BridgeMD
Defining the Glucagon Unit: Investigating the Impact on Energy Expenditure and Glucose Level Deviation in healthy volunteers
EU CTIS ID: 2024-510885-17-01
What this study is testing
The primary objective of this study is to define the glucagon unit by investigating its impact on energy expenditure, glucose level deviation in the presence and absence of incretin-stimulated insulin secretion, and comparing the results with intravenous (i/v) and oral (p/o) glucose uptake.
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18 - 40 years.
- Male sex
- BMI 25 - 34.9.
- Signed informed consent
You likely can't join if
- Not signed informed consent
- Abnormal laboratory results: ○ TSH < 0,4 or > 4,0 mIU/L ○ ALAT > 40 U/L ○ CKD (GFR < 90 ml/min/m2) ○ Abnormal fasting glucose (≥6.1 mmol/L) ○ abnormal HbA1c (≥5.7%) ○ Other significant deviations according to research team views
- Diabetes mellitus (any type).
- Current use of any anti-diabetic drugs (for any indication).
- Any other medical condition or treatment that, in the opinion of the investigator, would interfere with the study objectives, conduct, or interpretation of results.
- Inability to tolerate calorimeter canopy.
See the full eligibility criteria
- Age 18 - 40 years.
- Male sex
- BMI 25 - 34.9.
- Signed informed consent
- Not signed informed consent
- Abnormal laboratory results: ○ TSH < 0,4 or > 4,0 mIU/L ○ ALAT > 40 U/L ○ CKD (GFR < 90 ml/min/m2) ○ Abnormal fasting glucose (≥6.1 mmol/L) ○ abnormal HbA1c (≥5.7%) ○ Other significant deviations according to research team views
- Diabetes mellitus (any type).
- Current use of any anti-diabetic drugs (for any indication).
- Any other medical condition or treatment that, in the opinion of the investigator, would interfere with the study objectives, conduct, or interpretation of results.
- Inability to tolerate calorimeter canopy.
- Participants who have received any investigational product or medication within 180 days prior to screening.
- Participants who have donated blood or plasma within 30 days prior to screening.
- Participants who have a known allergy or intolerance to any of the study medications or their components.
- Inability to comply with study requirements
- BMI > 35 kg/m2 and < 25 kg/m2
- History of gastrointestinal disorders, surgery or other medical conditions that could affect nutrient absorption and/or predispose a subject to side effects of GLP-RA (chronic pancreatitis, dysmotility, rapidly growing thyroid nodules etc)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.